CRISPR-based nucleic acid detection

Technology class

CRISPR-based nucleic acid detection

Methods and systems for malaria detection using CRISPR-based nucleic acid detection platforms

CRISPR-based nucleic acid detection couples isothermal amplification with programmable CRISPR-Cas endonuclease systems to achieve ultrasensitive malaria parasite identification, potentially reaching single-digit parasites per microliter while maintaining the simplicity of a lateral-flow readout. This approach represents a convergence of molecular sensitivity with point-of-care form factors, though it remains firmly in the research and patent stage with no commercial malaria products identified.

Deployment TierReference laboratory
SensitivityMolecular
Field-readinessLab-based
Deletion-robustYes
Filing growth, 2014–23+21.3% a year
Top 4 holders hold30%
Patent holders120
Effective holders21
Commercial products2

Effective holders is the inverse of the HHI (1 ÷ HHI): a measure of how concentrated patent ownership is in this class.

Technology mechanism

CRISPR-based malaria detection typically employs a two-stage workflow beginning with isothermal preamplification of parasite nucleic acids using methods such as recombinase polymerase amplification (as in M5) or loop-mediated isothermal amplification (as in M4), followed by CRISPR-Cas-mediated target recognition and signal generation. The CRISPR component uses Cas12 or Cas13 enzymes programmed with guide RNAs targeting conserved Plasmodium sequences; upon binding the amplified target, these enzymes exhibit collateral cleavage activity that degrades reporter molecules to produce fluorescent or colorimetric signals detectable on lateral-flow strips. The combined workflow typically requires 45 to 90 minutes from sample to result, with the amplification step running at 37 to 42 degrees Celsius for 20 to 40 minutes and the CRISPR detection step adding 10 to 30 minutes at similar temperatures. Analytical sensitivity in research prototypes has demonstrated detection thresholds of 1 to 10 parasites per microliter, approaching PCR-level performance while avoiding thermocycling requirements. Unlike M4 and M5 which rely solely on amplification endpoint detection, the CRISPR layer adds sequence-specific verification that reduces false positives from nonspecific amplification, a persistent challenge with isothermal methods. Sample preparation remains a critical bottleneck; most published protocols require nucleic acid extraction steps that add 15 to 30 minutes and additional reagents, though simplified lysis approaches compatible with dried blood spots are under investigation. Multiplexing capability allows simultaneous detection of P. falciparum and P. vivax using distinct guide RNA sequences, with species differentiation achievable through spatial separation on lateral-flow strips or wavelength-resolved fluorescence.

Operational footprint

Current CRISPR-based malaria detection prototypes require modest infrastructure including a heat source maintaining 37 to 42 degrees Celsius, which can potentially be achieved through battery-powered heating blocks or chemical heating packs, though no field-validated malaria-specific devices exist. Power requirements are substantially lower than PCR but higher than standard RDTs (M1, M2), with heating elements typically drawing 5 to 15 watts for 60 to 90 minutes. Cold chain requirements depend on reagent formulation; lyophilized CRISPR-Cas complexes and amplification reagents can theoretically achieve ambient stability for weeks to months, but validated stability data under tropical conditions (35 to 45 degrees Celsius, high humidity) are not yet available for malaria-specific formulations. Training burden exceeds that of standard RDTs significantly, requiring operators to perform sample preparation, reagent reconstitution, precise timing of multiple incubation steps, and interpretation of results, likely necessitating 3 to 5 days of hands-on training compared to 1 to 2 days for conventional RDTs. Throughput is limited by the sequential workflow, with individual operators likely processing 4 to 8 samples per hour under optimal conditions, far below the throughput achievable with batched molecular methods (M8) or the rapid individual testing possible with RDTs. The technology is not currently deployed at any scale for malaria diagnosis; all evidence derives from controlled laboratory studies and small proof-of-concept evaluations.

Maturity signals

CRISPR-based malaria detection remains pre-commercial with no products identified in the commercial roster and no WHO prequalification or stringent regulatory authority clearance for any malaria application. Patent activity reveals substantial upstream investment, with 172 patents across 10 unique assignees dominated by academic and research institutions including Massachusetts Institute of Technology, Broad Institute, Harvard University, and University of California San Diego, reflecting the technology's origins in fundamental CRISPR biology rather than diagnostics-focused development. The assignee composition shows mechanism-aligned participation concentrated among platform technology holders rather than established diagnostics manufacturers, suggesting that translation to malaria-specific products will require licensing arrangements or partnerships with companies possessing regulatory and manufacturing expertise. Commercial CRISPR diagnostics entities have narrowed their focus, with Mammoth Biosciences scaling back diagnostics efforts in 2023 to focus on therapeutics and Sherlock Biosciences now operating under OraSure Technologies following acquisition in late 2024, neither with announced malaria programs. No clinical trial registrations for CRISPR-based malaria diagnostics were identified in the regulatory data provided, and the pathway to WHO prequalification remains undefined given the absence of precedent for this technology class in malaria.

Challenges

The multi-step workflow requiring nucleic acid extraction, isothermal amplification, and CRISPR detection creates multiple failure points and extends time-to-result beyond the 15 to 30 minutes acceptable for point-of-care malaria testing, contrasting sharply with the single-step simplicity of lateral-flow RDTs (M1, M2). Reagent complexity poses significant manufacturing and stability challenges, as CRISPR-Cas enzymes, guide RNAs, and amplification components each have distinct storage requirements and potential degradation pathways under field conditions. Intellectual property fragmentation across multiple academic institutions creates licensing complexity that may impede commercial development, particularly for manufacturers in endemic countries seeking to produce affordable diagnostics. The absence of any regulatory precedent for CRISPR-based diagnostics in the WHO prequalification pathway means that developers face uncertain timelines and requirements, with no established performance standards or evaluation protocols specific to this technology class. Cost projections remain speculative but likely exceed the WHO target of less than two dollars per test for ultrasensitive diagnostics, given the complexity of reagent production and the current absence of manufacturing scale. Sample preparation requirements incompatible with finger-prick whole blood without processing represent a fundamental barrier to community health worker deployment, where the operational simplicity of RDTs sets user expectations. Competition from maturing ultrasensitive RDT platforms (M3) and established isothermal amplification methods (M4, M5) that offer simpler workflows may limit the addressable use cases for CRISPR-based approaches to applications requiring the highest specificity, such as confirmation of low-density infections in elimination settings.

← Back to what’s inside this report